How can we improve adjuvant chemotherapy for colon cancer?

Affiliations

¹ Department of Clinical Oncology, St Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan. Electronic address: n.boku@marianna-u.ac.jp.

Comment

Narikazu Boku. Lancet Oncol. 2014 Dec.

. 2014 Dec;15(13):1413-1415.

doi: 10.1016/S1470-2045(14)71034-4. Epub 2014 Nov 12.

¹ Department of Clinical Oncology, St Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511 Japan. Electronic address: n.boku@marianna-u.ac.jp.

No abstract available

Comment on

Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials.
Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Schmoll HJ, et al. Lancet Oncol. 2014 Dec;15(13):1481-1492. doi: 10.1016/S1470-2045(14)70486-3. Epub 2014 Nov 12. Lancet Oncol. 2014. PMID: 25456367 Free PMC article. Clinical Trial.